Relationship Between Chemokine Levels And Viral Response To Pegifna-2A Treatment In Patients With Chronic Hepatitis B

Objective:To elucidate the possible association between serum chemokine levels and response to PegIFNa-2a treatment in patients with chronic hepatitis B.Methods:Thirty six patients with chronic HBV genotype B infection were recruited to this study, serum CXCL9、CXCL10、CCL3and CCL5concentrations were measured by an ELISA method at baseline and month3. All patients received PegIFNa-2a180ug every week and followed up for six months.Results:By binary logistic regression analysis of all patients, we found that pretreatment serum CXCL9was independent predictor for early virological response. At month3, the rates of early virological response was78.95%(15/19) and23.53%(4/17) in patients whose baseline serum CXCL9was higher and lower than39.51ng/1respectively(P<0.05); At month6, the rates of maintained response was63.16%(12/19) and 11.76%(2/17) in patients whose baseline serum CXCL9was higher and lower than39.51ng/L respectively(P<0.05).Conclusion:There are better outcome of PegIFNa-2a therapy for patients with higher CXCL9production, so detection of serum CXCL9baseline may help to improve the efficacy of PegIFNa-2a therapy for patients with chronic hepatitis B, especial for those infected with HBV genotype B.